Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
The in vitro activity of BMS-284756 against 602 Staphylococcus aureus isolates, including 152 that were both methicillin and ciprofloxacin resistant (MIC > or = 4 microg/ml), was determined. For ciprofloxacin-susceptible and nonsusceptible isolates, the MICs at which 50% of organisms were inhibited were 0.015 and 2 microg/ml and the MICs at which 90% of organisms were inhibited were 0.03 and 4 microg/ml, respectively.
Low
D E
DE
Department of Microbiology, Toronto Medical Laboratories and Mount Sinai Hospital, Toronto, Ontario, Canada. dlow@mtsinai.on.ca
Muller
M
M
Duncan
C L
CL
Willey
B M
BM
de Azavedo
J C
JC
McGeer
A
A
Kreiswirth
B N
BN
Pong-Porter
S
S
Bast
D J
DJ
D019943:Amino Acid Substitution; D000890:Anti-Infective Agents / Q000494:pharmacology*; D027081:DNA Gyrase / Q000235:genetics; D027101:DNA Topoisomerase IV / Q000037:antagonists & inhibitors / Q000235:genetics; D004269:DNA, Bacterial / Q000187:drug effects / Q000235:genetics; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006801:Humans; D007211:Indoles; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics*; D015363:Quinolones; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics*; D059005:Topoisomerase II Inhibitors
D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; D059005:Topoisomerase II Inhibitors; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase; C419689:garenoxacin